# IMvigor211 (NCT02302807)

> A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

No report yet. It can be ordered.

- Drugs tested: atezolizumab
- Indication: platinum-treated locally advanced or metastatic urothelial carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02302807
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Bladder Cancer
- Interventions: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody; Docetaxel; Paclitaxel; Vinflunine
- Enrollment: 931
- Primary outcome: Overall Survival (OS)

## Questions raised in the commentary

_Automated from the 23 newest of 27 indexed sources (Dec 2017 – Mar 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether IMvigor211 excludes a second-line role for atezolizumab
- Whether biomarkers can reliably identify patients more likely to benefit from atezolizumab
- Whether molecular subtypes can guide treatment selection

Also discussed: serum sodium as a biomarker.

## Indexed commentary on IMvigor211 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 23
- Podcasts: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=imvigor211-nct02302807

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02302807", "email": "<work email>"}; the inbox owner confirms by the emailed link.